Role of sevelamer carbonate in the treatment of hyperphosphatemia in the chronic kidney disease patients on hemodialysis therapy
Other Title(s)
دور كريونات سيفيلامير في علاج فرط فوسفات الدم عند مرض الأمراض الكلوية المزمنة الموضوعين على التحال الدموي
Joint Authors
Manati, Jawad Kazim
Abbas, Ahmad Asi
Source
Journal of the Arab Board of Health Specializations
Issue
Vol. 21, Issue 1 (31 Mar. 2020), pp.13-18, 6 p.
Publisher
The Arab Board of Health Specializations
Publication Date
2020-03-31
Country of Publication
Syria
No. of Pages
6
Main Subjects
Abstract EN
Objective: Hyperphosphataemia is a frequent complication in patients with chronic kidney disease (CKD), particularly in those with end-stage renal disease, and there is considerable evidence that inadequate phosphorus control is associated with increased morbidity and mortality.
The aim of this study and physical examination at baseline, all patients were taken calcium carbonate tablets, and half of them were received sevelamer carbonate tablets for a period of six months (24 weeks).
The investigations include blood urea, serum creatinine, calcium, phosphorus, alkaline phosphatase and parathyroid hormone.
Results: Sevelamer carbonate plus calcium carbonate made a significant reduction in serum phosphorus, parathyroid hormone and serum calcium levels when compared with calcium carbonate received patients, serum phosphorus correlated positively with s.PTH while negatively with s.Ca.
Conclusions: Sevelamer carbonate was effective and safe in hyperphosphataemia patients with chronic renal failure on hemodialysis.
American Psychological Association (APA)
Manati, Jawad Kazim& Abbas, Ahmad Asi. 2020. Role of sevelamer carbonate in the treatment of hyperphosphatemia in the chronic kidney disease patients on hemodialysis therapy. Journal of the Arab Board of Health Specializations،Vol. 21, no. 1, pp.13-18.
https://search.emarefa.net/detail/BIM-1271988
Modern Language Association (MLA)
Manati, Jawad Kazim& Abbas, Ahmad Asi. Role of sevelamer carbonate in the treatment of hyperphosphatemia in the chronic kidney disease patients on hemodialysis therapy. Journal of the Arab Board of Health Specializations Vol. 21, no. 1 (2020), pp.13-18.
https://search.emarefa.net/detail/BIM-1271988
American Medical Association (AMA)
Manati, Jawad Kazim& Abbas, Ahmad Asi. Role of sevelamer carbonate in the treatment of hyperphosphatemia in the chronic kidney disease patients on hemodialysis therapy. Journal of the Arab Board of Health Specializations. 2020. Vol. 21, no. 1, pp.13-18.
https://search.emarefa.net/detail/BIM-1271988
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 17-18
Record ID
BIM-1271988